Navigation Links
Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College
Date:1/14/2014

VALHALLA, N.Y., Jan. 14, 2014 /PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today the relocation of its corporate headquarters to Valhalla, NY as of January 15, 2014 and expanded lease agreement for additional laboratory space at New York Medical College.

Oligomerix, which is focused on the development of small molecule drugs aimed specifically at inhibiting tau aggregation at the earliest steps of tau self-association into toxic oligomers in neurons, has continued to successfully advance its research, resulting in the need to add staff and expand its office and lab space.

"We're extremely encouraged by the preclinical data we've observed in our lead small molecule program, and are eager to continue our research in this space," stated James Moe, Ph.D., MBA, President and CEO of Oligomerix.  "As New York Medical College is already providing space for in vivo mouse studies for our lead compound, we believe the decision to move and expand Oligomerix's corporate headquarters will benefit the company's logistical needs."

Oligomerix recently announced the appointment of James Hendrix, Ph.D., as the company's Senior Director of Chemistry, and plans to potentially recruit up to five employees in 2014.

ABOUT OLIGOMERIXOligomerix, Inc. is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. Founded in 2006, the Company is headquartered in Valhalla, NY and is carrying out its in vivo studies at New York Medical College.  The Company is seeking strategic partners to help accelerate these exciting programs.  For more information, visit www.oligomerix.com.

Certain matters described in this news release may be forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risk of dependence on market growth, competition and dependence on government agencies and other third parties for funding contract research and services. CONTACTS: Oligomerix, Inc.  7 Legion Drive, Valhalla, NY

Tiberend Strategic Advisors, Inc. Jack Pasini 

Andrew Mielach  Chief Commercial Officer 

212-375-2694 917-912-4088

amielach@tiberend.com  jpasini@oligomerix.com 


'/>"/>
SOURCE Oligomerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Oligomerix Awarded Phase IIB Grant From the NIH to Discover Drugs that Inhibit Alzheimers Disease Progression
2. Ultragenyx Relocates Company Headquarters to Support Operational Expansion
3. ImmusanT Relocates Offices to State-of-the-Art Innovation Facility
4. Sysmex America Relocates Corporate Headquarters
5. HemoShear Relocates and Expands Operations to Historic Martha Jefferson Property in Charlottesville, Virginia
6. Growth Fuels Expansion As PendoTECH Relocates New Jersey Headquarters
7. Optimal Radiology Relocates Headquarters to Nashville
8. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
9. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
10. Survey Shows eContent Critical to Corporate Strategies
11. Medical Marijuana Inc. (MJNA) Corporate Update on Industry Company Services and Future Development. First Audio-Webcast Interview With SmallCapVoice.com in Quarterly Series
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... , Feb. 27, 2017 This report ... Teva and its partnering interests and activities since 2010. ... Description The Partnering Deals and Alliance since ... activity of one of the world,s leading life sciences ... upon purchase to ensure inclusion of the most up ...
(Date:2/27/2017)... The report "(CTMS)  Clinical Trial Management System Market ... Based), By Delivery Mode (Web, Cloud, On Premise), By End Use (Pharmaceutical ... Outlook (U.S., Canada , Germany , ... Russia , China , India ... , Taiwan , Brazil , ...
(Date:2/27/2017)... Feb. 27, 2017   Royal Philips ... global leader in health technology, today announced 510(k) ... (FDA) to market its ElastQ Imaging capability, further ... ultrasound systems. ElastQ Imaging enables simultaneous imaging of ... essential for the diagnosis of various liver conditions. ...
Breaking Medicine Technology:
(Date:2/28/2017)... ... February 28, 2017 , ... The role of females ... from military to civilian life. Body image dissatisfaction is largely unexamined among female ... and greater occurrence of chronic mental health conditions than female civilians. Female veterans ...
(Date:2/27/2017)... ... February 27, 2017 , ... Robert E. Burke, MD, PhD, had a ... impoverished upbringing and life experiences could have led him down a much different path. ... Tales of Parenting, Perseverance and Pediatrics,” Dr. Burke shares a personal account of the ...
(Date:2/27/2017)... ... February 27, 2017 , ... Orange County dentist, ... inflammatory gum condition that occurs when the bacteria in plaque infect the gums and ... as a scaling and root planing or SRP, and can include surgical therapies if ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... alcohol treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud ... The new hire, Mackenzie Alsager, showcases the Centre's commitment to innovation in drug ...
(Date:2/26/2017)... ... 2017 , ... Today, A' Design Awards & Competition has ... Design Awards. , The 7th A' Social Design Award is open for ... with realized projects and conceptual works. , The first phase of the International ...
Breaking Medicine News(10 mins):